Adalimumab for Ocular Inflammation

Khayyam Durrani^{1

2}, John H Kempen^{3

4}, Gui-Shuang Ying³, R Oktay Kacmaz¹, Pichaporn Artornsombudh^{1

3}, James T Rosenbaum^{5

6}, Eric B Suhler^{5

6

7}, Jennifer E Thorne^{8

9}, Douglas A Jabs^{9

10

11}, Grace A Levy-Clarke¹², Robert B Nussenblatt¹², C Stephen Foster Md Facs^{1

2}, Systemic Immunosuppressive Therapy For Eye Diseases Site Research Group

Affiliations

¹ a Massachusetts Eye Research & Surgery Institution and Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.
² b Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
³ c Center for Preventive Ophthalmology and Biostatistics.
⁴ d Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics & Epidemiology , Perelman School of Medicine, University of Pennsylvania , Philadelphia , Pennsylvania , USA.
⁵ e Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
⁶ f Department of Medicine , Oregon Health and Science University , Portland , Oregon , USA.
⁷ g Portland Veteran's Affairs Medical Center , Portland , Oregon , USA.
⁸ h Department of Ophthalmology , Johns Hopkins University School of Medicine , Baltimore , Maryland , USA.
⁹ i Johns Hopkins University Bloomberg School of Public Health , Baltimore , Maryland , USA.
¹⁰ j Department of Ophthalmology , Icahn School of Medicine at Mount Sinai , New York , New York , USA.
¹¹ k Department of Medicine , Icahn School of Medicine at Mount Sinai , New York , New York , USA.
¹² l Laboratory of Immunology, National Eye Institute , Bethesda , Maryland , USA.

PMID: 27003323
PMCID: PMC5033708
DOI: 10.3109/09273948.2015.1134581

Multicenter Study

Adalimumab for Ocular Inflammation

Khayyam Durrani et al. Ocul Immunol Inflamm. 2017 Jun.

. 2017 Jun;25(3):405-412.

doi: 10.3109/09273948.2015.1134581. Epub 2016 Mar 22.

Authors

Affiliations

¹ a Massachusetts Eye Research & Surgery Institution and Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.
² b Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
³ c Center for Preventive Ophthalmology and Biostatistics.
⁴ d Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics & Epidemiology , Perelman School of Medicine, University of Pennsylvania , Philadelphia , Pennsylvania , USA.
⁵ e Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
⁶ f Department of Medicine , Oregon Health and Science University , Portland , Oregon , USA.
⁷ g Portland Veteran's Affairs Medical Center , Portland , Oregon , USA.
⁸ h Department of Ophthalmology , Johns Hopkins University School of Medicine , Baltimore , Maryland , USA.
⁹ i Johns Hopkins University Bloomberg School of Public Health , Baltimore , Maryland , USA.
¹⁰ j Department of Ophthalmology , Icahn School of Medicine at Mount Sinai , New York , New York , USA.
¹¹ k Department of Medicine , Icahn School of Medicine at Mount Sinai , New York , New York , USA.
¹² l Laboratory of Immunology, National Eye Institute , Bethesda , Maryland , USA.

PMID: 27003323
PMCID: PMC5033708
DOI: 10.3109/09273948.2015.1134581

Abstract

Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases.

Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity.

Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months.

Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

Keywords: Adalimumab; Humira; TNF-α antibody; ocular inflammatory disease; scleritis; uveitis.

PubMed Disclaimer

Comment in

Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation".
Ghembaza MEA, Lounici A. Ghembaza MEA, et al. Ocul Immunol Inflamm. 2019;27(1):70. doi: 10.1080/09273948.2017.1371312. Epub 2017 Oct 11. Ocul Immunol Inflamm. 2019. PMID: 29020494 No abstract available.

References

1. Yoshida M, Yoshimura N, Hangai M, et al. Interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1994;35:1107–1113. - PubMed
1. Michalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep. 2008;8:339–347. - PubMed
1. Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117–144. - PubMed
1. Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121–136. - PMC - PubMed
1. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–324. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adalimumab for Ocular Inflammation

Affiliations

Adalimumab for Ocular Inflammation

Authors

Affiliations

Abstract

Comment in

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources